Agios Pharmaceuticals Inc (AGIO) Major Shareholder Corp /De/ Celgene Purchases 851,154 Shares

Agios Pharmaceuticals Inc (NASDAQ:AGIO) major shareholder Corp /De/ Celgene acquired 851,154 shares of the stock in a transaction on Tuesday, January 23rd. The shares were bought at an average price of $67.00 per share, for a total transaction of $57,027,318.00. Following the purchase, the insider now owns 1,374,599 shares in the company, valued at $92,098,133. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Agios Pharmaceuticals Inc (AGIO) traded up $0.85 on Tuesday, hitting $79.20. The stock had a trading volume of 1,574,868 shares, compared to its average volume of 689,584. Agios Pharmaceuticals Inc has a one year low of $39.24 and a one year high of $80.10. The company has a market cap of $3,860.00, a price-to-earnings ratio of -12.63 and a beta of 1.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same quarter last year, the company posted ($1.63) EPS. The company’s revenue for the quarter was up 26.4% compared to the same quarter last year. equities analysts expect that Agios Pharmaceuticals Inc will post -6.59 earnings per share for the current year.

A number of equities analysts have commented on the company. Zacks Investment Research lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Royal Bank of Canada raised their price objective on Agios Pharmaceuticals to $91.00 and gave the stock an “outperform” rating in a research note on Thursday, January 18th. They noted that the move was a valuation call. SunTrust Banks restated a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Finally, Credit Suisse Group lifted their price target on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $77.64.

Institutional investors and hedge funds have recently modified their holdings of the company. Hood River Capital Management LLC grew its position in Agios Pharmaceuticals by 2.3% during the 2nd quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock worth $6,115,000 after acquiring an additional 2,626 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Agios Pharmaceuticals by 4.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 681,093 shares of the biopharmaceutical company’s stock worth $35,042,000 after acquiring an additional 31,969 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth $743,000. Royal Bank of Canada grew its position in Agios Pharmaceuticals by 40.8% during the 2nd quarter. Royal Bank of Canada now owns 9,131 shares of the biopharmaceutical company’s stock worth $470,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its position in Agios Pharmaceuticals by 21.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock worth $2,572,000 after acquiring an additional 8,965 shares during the last quarter. Institutional investors own 93.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Agios Pharmaceuticals Inc (AGIO) Major Shareholder Corp /De/ Celgene Purchases 851,154 Shares” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/23/agios-pharmaceuticals-inc-agio-major-shareholder-corp-de-celgene-purchases-851154-shares.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply